{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:09:59Z","timestamp":1746331799652},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00292-021-00965-2","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T08:03:56Z","timestamp":1629187436000},"page":"464-471","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Das duktale Adenokarzinom des Pankreas: Subtypen und Molekularpathologie"],"prefix":"10.1007","volume":"42","author":[{"given":"Anna Melissa","family":"Schlitter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Konukiewitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Kasajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Kl\u00f6ppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"965_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/00000478-200305000-00002","volume":"27","author":"NV Adsay","year":"2003","unstructured":"Adsay\u00a0NV, Merati\u00a0K, Nassar\u00a0H et al (2003) Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am J Surg Pathol 27:571\u2013578","journal-title":"Am J Surg Pathol"},{"key":"965_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/modpathol.2014.100","volume":"28","author":"A Agaimy","year":"2015","unstructured":"Agaimy\u00a0A, Haller\u00a0F, Frohnauer\u00a0J et\u00a0al (2015) Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. Mod Pathol 28:248\u2013260","journal-title":"Mod Pathol"},{"key":"965_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey\u00a0P, Chang\u00a0DK, Nones\u00a0K et\u00a0al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47\u201352","journal-title":"Nature"},{"key":"965_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran\u00a0VP, Luksza\u00a0M, Zhao\u00a0JN et al (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551:512\u2013516","journal-title":"Nature"},{"key":"965_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ccell.2020.02.010","volume":"37","author":"F Bednar","year":"2020","unstructured":"Bednar\u00a0F, Pasca Di Magliano\u00a0M (2020) Context-dependent immune responses explain pancreatic cancer immunoresistance. Cancer Cell 37:261\u2013263","journal-title":"Cancer Cell"},{"key":"965_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin\u00a0AV, Waddell\u00a0N, Kassahn\u00a0KS et\u00a0al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399\u2013405","journal-title":"Nature"},{"key":"965_CR7","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny\u00a0B, Semenisty\u00a0V, Macarulla\u00a0T et al (2020) BL-8040, a\u00a0CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med 26:878\u2013885","journal-title":"Nat Med"},{"key":"965_CR8","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley\u00a0JD, Gospodarowicz\u00a0MK, Wittekind\u00a0C (2017) TNM classification of malignant tumours, 8.\u00a0Aufl. John Wiley & Sons, Hoboken","edition":"8"},{"key":"965_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.annonc.2020.11.013","volume":"32","author":"R Casolino","year":"2021","unstructured":"Casolino\u00a0R, Braconi\u00a0C, Malleo\u00a0G et\u00a0al (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann Oncol 32:183\u2013196","journal-title":"Ann Oncol"},{"key":"965_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","volume":"16","author":"EA Collisson","year":"2019","unstructured":"Collisson\u00a0EA, Bailey\u00a0P, Chang\u00a0DK et\u00a0al (2019) Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 16:207\u2013220","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"965_CR11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson\u00a0EA, Sadanandam\u00a0A, Olson\u00a0P et\u00a0al (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17:500\u2013503","journal-title":"Nat Med"},{"key":"965_CR12","doi-asserted-by":"publisher","first-page":"13833","DOI":"10.3748\/wjg.v20.i38.13833","volume":"20","author":"I Esposito","year":"2014","unstructured":"Esposito\u00a0I, Konukiewitz\u00a0B, Schlitter\u00a0AM et\u00a0al (2014) Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments. World J Gastroenterol 20:13833\u201313841","journal-title":"World J Gastroenterol"},{"key":"965_CR13","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.pan.2015.08.007","volume":"15","author":"I Esposito","year":"2015","unstructured":"Esposito\u00a0I, Segler\u00a0A, Steiger\u00a0K et\u00a0al (2015) Pathology, genetics and precursors of human and experimental pancreatic neoplasms: an update. Pancreatology 15:598\u2013610","journal-title":"Pancreatology"},{"key":"965_CR14","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig\u00a0C, Jones\u00a0JO, Kraman\u00a0M et al (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S\u00a0A 110:20212\u201320217","journal-title":"Proc Natl Acad Sci U S A"},{"key":"965_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan\u00a0T, Hammel\u00a0P, Reni\u00a0M et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N\u00a0Engl J Med 381:317\u2013327","journal-title":"N Engl J Med"},{"key":"965_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/2159-8290.CD-18-0036","volume":"8","author":"C Heining","year":"2018","unstructured":"Heining\u00a0C, Horak\u00a0P, Uhrig\u00a0S et al (2018) NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov 8:1087\u20131095","journal-title":"Cancer Discov"},{"key":"965_CR17","first-page":"322","volume-title":"WHO classification of tumours. Digestive system tumours","author":"RH Hruban","year":"2019","unstructured":"Hruban\u00a0RH, Adsay\u00a0NV, Esposito\u00a0I et\u00a0al (2019) Pancreatic ductal adenocarcinoma. In: WHO Classification of Tumours Editorial Board (Hrsg) WHO classification of tumours. Digestive system tumours. IARC Press, Lyon, S\u00a0322\u2013332"},{"key":"965_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cell.2019.02.049","volume":"177","author":"FW Huang","year":"2019","unstructured":"Huang\u00a0FW, Feng\u00a0FY (2019) A tumor-agnostic NTRK (TRK) inhibitor. Cell 177:8","journal-title":"Cell"},{"key":"965_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/j.gastro.2016.09.060","volume":"152","author":"JL Humphris","year":"2017","unstructured":"Humphris\u00a0JL, Patch\u00a0AM, Nones\u00a0K et\u00a0al (2017) Hypermutation in pancreatic cancer. Gastroenterology 152:68\u201374.e2","journal-title":"Gastroenterology"},{"key":"965_CR20","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang\u00a0H, Hegde\u00a0S, Knolhoff\u00a0BL et\u00a0al (2016) Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 22:851\u2013860","journal-title":"Nat Med"},{"key":"965_CR21","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-19-0191","volume":"25","author":"MR Jones","year":"2019","unstructured":"Jones\u00a0MR, Williamson\u00a0LM, Topham\u00a0JT et al (2019) NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma. Clin Cancer Res 25:4674\u20134681","journal-title":"Clin Cancer Res"},{"key":"965_CR22","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones\u00a0S, Zhang\u00a0X, Parsons\u00a0DW et\u00a0al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801\u20131806","journal-title":"Science"},{"issue":"7","key":"965_CR23","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1245\/s10434-017-5810-x","volume":"24","author":"SK Kamarajah","year":"2017","unstructured":"Kamarajah\u00a0SK, Burns\u00a0WR, Frankel\u00a0TL et\u00a0al (2017) Validation of the American joint commission on cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: a surveillance, epidemiology and end results (SEER) analysis. Ann Surg Oncol 24(7):2023\u20132030. https:\/\/doi.org\/10.1245\/s10434-017-5810-x","journal-title":"Ann Surg Oncol"},{"key":"965_CR24","first-page":"708","volume-title":"PATHOLOGIE \u2013 Leber, Gallenwege und Pankreas","author":"G Kl\u00f6ppel","year":"2020","unstructured":"Kl\u00f6ppel\u00a0G, Esposito\u00a0I, Kasajima\u00a0A et\u00a0al (2020) Solide und zystische nichtendokrine Tumoren des Pankreas. In: Tannapfel\u00a0A, Kl\u00f6ppel\u00a0G (Hrsg) PATHOLOGIE \u2013 Leber, Gallenwege und Pankreas. Springer, , S\u00a0708\u2013774"},{"key":"965_CR25","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/2159-8290.CD-20-0519","volume":"11","author":"J Li","year":"2021","unstructured":"Li\u00a0J, Yuan\u00a0S, Norgard\u00a0RJ et\u00a0al (2021) Epigenetic and transcriptional control of the epidermal growth factor receptor regulates the tumor immune microenvironment in pancreatic cancer. Cancer Discov 11:736\u2013753","journal-title":"Cancer Discov"},{"key":"965_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13046-020-01732-6","volume":"39","author":"C Luchini","year":"2020","unstructured":"Luchini\u00a0C, Paolino\u00a0G, Mattiolo\u00a0P et al (2020) KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J\u00a0Exp Clin Cancer Res 39:227","journal-title":"J Exp Clin Cancer Res"},{"key":"965_CR27","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1053\/j.gastro.2018.08.009","volume":"155","author":"UM Mahajan","year":"2018","unstructured":"Mahajan\u00a0UM, Langhoff\u00a0E, Goni\u00a0E et al (2018) Immune cell and stromal signature associated with progression-free survival of patients with resected pancreatic ductal adenocarcinoma. Gastroenterology 155:1625\u20131639.e2","journal-title":"Gastroenterology"},{"key":"965_CR28","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt\u00a0RA, Marayati\u00a0R, Flate\u00a0EL et al (2015) Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 47:1168\u20131178","journal-title":"Nat Genet"},{"key":"965_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/1078-0432.CCR-17-2180","volume":"24","author":"A Muckenhuber","year":"2018","unstructured":"Muckenhuber\u00a0A, Berger\u00a0AK, Schlitter\u00a0AM et al (2018) Pancreatic ductal adenocarcinoma subtyping using the biomarkers hepatocyte nuclear factor-1A and cytokeratin-81 correlates with outcome and treatment response. Clin Cancer Res 24:351\u2013359","journal-title":"Clin Cancer Res"},{"key":"965_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nm.4038","volume":"22","author":"EM Noll","year":"2016","unstructured":"Noll\u00a0EM, Eisen\u00a0C, Stenzinger\u00a0A et\u00a0al (2016) CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 22:278\u2013287","journal-title":"Nat Med"},{"key":"965_CR31","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019kane","year":"2020","unstructured":"O\u2019kane\u00a0GM, Grunwald\u00a0BT, Jang\u00a0GH et al (2020) GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res 26:4901\u20134910","journal-title":"Clin Cancer Res"},{"key":"965_CR32","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly\u00a0EM, Lee\u00a0JW, Zalupski\u00a0M et\u00a0al (2020) Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a\u00a0germline BRCA\/PALB2 mutation. J\u00a0Clin Oncol 38:1378\u20131388","journal-title":"J Clin Oncol"},{"key":"965_CR33","unstructured":"Robert Koch Institut (2021) Bauchspeicheldr\u00fcsenkrebs (Pankreaskarzinom). https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Bauchspeicheldruesenkrebs\/bauchspeicheldruesenkrebs_node.html. Zugegriffen: 21. Mai 2021"},{"key":"965_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2017.06.034","volume":"84","author":"AM Schlitter","year":"2017","unstructured":"Schlitter\u00a0AM, Jesinghaus\u00a0M, Jager\u00a0C et\u00a0al (2017) pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Eur J Cancer 84:121\u2013129","journal-title":"Eur J Cancer"},{"key":"965_CR35","doi-asserted-by":"publisher","first-page":"41064","DOI":"10.1038\/srep41064","volume":"7","author":"AM Schlitter","year":"2017","unstructured":"Schlitter\u00a0AM, Segler\u00a0A, Steiger\u00a0K et\u00a0al (2017) Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): identification of prognostic subtypes. Sci Rep 7:41064","journal-title":"Sci Rep"},{"key":"965_CR36","volume-title":"UICC TNM classification of malignant tumours","author":"LH Sobin","year":"2009","unstructured":"Sobin\u00a0LH, Gospodarowicz\u00a0MK, Wittekind\u00a0C (2009) UICC TNM classification of malignant tumours. Wiley-Blackwell, Hoboken (New Jersey), US"},{"key":"965_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell\u00a0N, Pajic\u00a0M, Patch\u00a0AM et\u00a0al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495\u2013501","journal-title":"Nature"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-021-00965-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-021-00965-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-021-00965-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T13:44:07Z","timestamp":1673099047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-021-00965-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1007\/s00292-021-00965-2","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"30 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0M.\u00a0Schlitter ist als wissenschaftliche Beraterin f\u00fcr BioNTech SE, Mainz t\u00e4tig. M.\u00a0Reichert ist als wissenschaftlicher Berater f\u00fcr Celgene, Roche und die Falk Foundation t\u00e4tig. G.\u00a0Kl\u00f6ppel hat Vortragshonorare von Novartis und Ipsen erhalten. B.\u00a0Konukiewitz und A.\u00a0Kasajima geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}